Dolors Colomer

28.6k total citations · 1 hit paper
280 papers, 12.0k citations indexed

About

Dolors Colomer is a scholar working on Genetics, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Dolors Colomer has authored 280 papers receiving a total of 12.0k indexed citations (citations by other indexed papers that have themselves been cited), including 169 papers in Genetics, 110 papers in Molecular Biology and 103 papers in Pathology and Forensic Medicine. Recurrent topics in Dolors Colomer's work include Chronic Lymphocytic Leukemia Research (146 papers), Lymphoma Diagnosis and Treatment (101 papers) and Chronic Myeloid Leukemia Treatments (32 papers). Dolors Colomer is often cited by papers focused on Chronic Lymphocytic Leukemia Research (146 papers), Lymphoma Diagnosis and Treatment (101 papers) and Chronic Myeloid Leukemia Treatments (32 papers). Dolors Colomer collaborates with scholars based in Spain, Germany and United States. Dolors Colomer's co-authors include Elı́as Campo, Neus Villamor, Emili Montserrat, Beatríz Bellosillo, Gaël Roué, Pedro Jares, Francesc Bosch, Armando López‐Guillermo, Patricia Pérez‐Galán and Joan Gil and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Circulation.

In The Last Decade

Dolors Colomer

270 papers receiving 11.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia

2003 970 citations Francesc Bosch, Neus Villamor et al. profile →

Peers

Countries citing papers authored by Dolors Colomer

Since Specialization

Citations

This map shows the geographic impact of Dolors Colomer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dolors Colomer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dolors Colomer more than expected).

Fields of papers citing papers by Dolors Colomer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dolors Colomer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dolors Colomer. The network helps show where Dolors Colomer may publish in the future.

Co-authorship network of co-authors of Dolors Colomer

This figure shows the co-authorship network connecting the top 25 collaborators of Dolors Colomer. A scholar is included among the top collaborators of Dolors Colomer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dolors Colomer. Dolors Colomer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology 2024 ·Annals of Hematology ·(unknown), Mònica López‐Guerra, Juan Carlos García‐Pagán, Eduardo Arellano‐Rodrigo, Francisca Ferrer‐Marín, Juan Carlos Hernández‐Boluda, Beatríz Bellosillo, Meritxell Nomdedéu, Virginia Hernández–Gea, (unknown), Francesca Guijarro, (unknown), Anna Baiges, Fanny Turón, Dolors Colomer, Francisco Cervantes, Alberto Álvarez‐Larrán	1
2	Identification of GNAS and KRAS in EUS-guided fluid samples from the main pancreatic duct (MPD) accurately discriminates Intraductal Papillary Mucinous Neoplasm (IPMN) from other conditions with MPD dilatation 2023 ·Endoscopy ·(unknown), (unknown), (unknown), Isis K. Araujo, Oriol Sendino, Henry Córdova, (unknown), Míriam Cuatrecasas, Glòria Fernández‐Esparrach, Dolors Colomer, Àngels Ginès, Eva C. Vaquero	0
3	SF3B1mutation–mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia 2023 ·Life Science Alliance ·Irene López‐Oreja, André Gohr, (unknown), (unknown), Fabián Arenas, Morihiro Higashi, (unknown), Mònica López‐Guerra, Manuel Irimia, Marta Aymerich, Juan Valcárcel, Sophie Bonnal, Dolors Colomer	8
4	Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes 2022 ·Cancers ·(unknown), Mònica López‐Guerra, (unknown), Álex Bataller, (unknown), (unknown), Francesca Guijarro, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sı́lvia Beà, Dolors Costa, Dolors Colomer, Marı́a Rozman, Jordi Esteve, Marina Díaz‐Beyá	9
5	EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia 2021 ·Leukemia ·Philipp M. Roessner, Laura Llaó Cid, (unknown), Tobias Roider, (unknown), (unknown), (unknown), (unknown), Fabian Kilpert, (unknown), Sebastian J. Arnold, Leopold Sellner, Dolors Colomer, Stephan Stilgenbauer, Sascha Dietrich, Peter Lichter, Ana Ízcue, Martina Seiffert	30
6	Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation 2021 ·Nature Communications ·Roser Vilarrasa‐Blasi, Paula Soler-Vila, Núria Verdaguer-Dot, Núria Russiñol, Marco Di Stefano, Vicente Chapaprieta, Guillem Clot, Irene Farabella, Pol Cuscó, Marta Kulis, Xabier Agirre, Felipe Prósper, Renée Beekman, Sı́lvia Beà, Dolors Colomer, Hendrik G. Stunnenberg, Marta Gut, Elı́as Campo, Marc A. Martı́-Renom, José I. Martı́n-Subero	76
7	EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia 2021 ·Leukemia ·Laura Llaó Cid, Philipp M. Roessner, Vicente Chapaprieta, Selcen Öztürk, Tobias Roider, (unknown), Ana Ízcue, Dolors Colomer, Sascha Dietrich, Stephan Stilgenbauer, Bola S. Hanna, José I. Martı́n-Subero, Martina Seiffert	29
8	Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network 2021 ·Journal of Cancer Research and Clinical Oncology ·Vivien Schäfer, Helen White, Gareth Gerrard, (unknown), Susanne Saußele, Georg‐Nikolaus Franke, (unknown), Rodica Tălmaci, Dolors Colomer, Simona Soverini, Kateřina Machová Poláková, Nicholas C.P. Cross, Andreas Hochhaus, Thomas Ernst	17
9	Clonal relationship in multisited mucosa‐associated lymphoid tissue lymphomas: a single‐centre experience 2020 ·British Journal of Haematology ·(unknown), Fina Climent, (unknown), Dolors Colomer, Mònica López‐Guerra, Mar Varela, (unknown), Clara Maluquer, Santiago Mercadal, Ana Carla Oliveira, (unknown), Xavier Matías‐Guiu, Eva González‐Barca, Anna Sureda, Eva Domingo‐Doménech	0
10	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia 2016 ·Clinical Cancer Research ·Sarah E. M. Herman, Arnau Montraveta, Carsten Utoft Niemann, Helena Mora-Jensen, Michael Gulrajani, Fanny Krantz, Rose Mantel, Lisa L. Smith, Fabienne McClanahan, Bonnie K. Harrington, Dolors Colomer, Todd Covey, John C. Byrd, Raquel Izumi, Allard Kaptein, Roger G. Ulrich, Amy J. Johnson, Brian J. Lannutti, Adrian Wiestner, Jennifer A. Woyach	121
11	The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia 2016 ·Clinical Cancer Research ·Alba Matas‐Céspedes, (unknown), Vanina Rodríguez, Neus Villamor, Julio Delgado, Eva Giné, Heleia Roca-Ho, Pablo Menéndez, Elı́as Campo, Armando López‐Guillermo, Dolors Colomer, Gaël Roué, Adrian Wiestner, Paul W.H.I. Parren, Parul Doshi, Jeroen Lammerts van Bueren, Patricia Pérez‐Galán	45
12	MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome 2016 ·Clinical Cancer Research ·Jordina Rovira, Kennosuke Karube, Alexandra Valera, Dolors Colomer, Anna Enjuanes, Luís Colomo, Alejandra Martínez‐Trillos, Eva Giné, Iván Dlouhy, Laura Magnano, Julio Delgado, Antonio Martı́nez, Neus Villamor, Elı́as Campo, Armando López‐Guillermo	50
13	Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib) 2014 ·Clinical Cancer Research ·Alba Matas‐Céspedes, Vanina Rodríguez, Susana G. Kalko, (unknown), Laia Rosich, (unknown), Patricia Balsas, Neus Villamor, Eva Giné, Elı́as Campo, Gaël Roué, Armando López‐Guillermo, Dolors Colomer, Patricia Pérez‐Galán	21
14	Antitumoral Activity of Lenalidomide in In Vitro and In Vivo Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27KIP1 Complexes 2013 ·Clinical Cancer Research ·Alexandra Moros, (unknown), Julie Cahu, Ifigènia Saborit-Villarroya, Antonio Martı́nez, Dolors Colomer, Brigitte Sola, Gaël Roué	17
15	Counteracting Autophagy Overcomes Resistance to Everolimus in Mantle Cell Lymphoma 2012 ·Clinical Cancer Research ·Laia Rosich, Sílvia Xargay‐Torrent, Mònica López‐Guerra, Elı́as Campo, Dolors Colomer, Gaël Roué	57
16	In vitro and In vivo Selective Antitumor Activity of Edelfosine against Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Involving Lipid Rafts 2010 ·Clinical Cancer Research ·Faustino Mollinedo, Janis de la Iglesia-Vicente, Consuelo Gajate, Ander Estella‐Hermoso de Mendoza, Janny A. Villa-Pulgarín, Mercè de Frías, Gaël Roué, Joan Gil, Dolors Colomer, Miguel Ángel Campanero, María J. Blanco‐Prieto	81
17	MicroRNA Expression, Chromosomal Alterations, and Immunoglobulin Variable Heavy Chain Hypermutations in Mantle Cell Lymphomas 2009 ·Cancer Research ·Alba Navarro, Sı́lvia Beà, Verónica Fernández, (unknown), Itziar Salaverría, Pedro Jares, Elena Hartmann, Anna Mozos, Armando López‐Guillermo, Neus Villamor, Dolors Colomer, Xavier Puig, German Ott, Françesc Solé, Sergi Serrano, Andreas Rosenwald, Elı́as Campo, Luís Hernández	60
18	Genetic Variants in Apoptosis and Immunoregulation-Related Genes Are Associated with Risk of Chronic Lymphocytic Leukemia 2008 ·Cancer Research ·Anna Enjuanes, Yolanda Benavente, Francesc Bosch, Idoia Martín‐Guerrero, Dolors Colomer, Susana Pérez-Álvarez, Óscar Reina, María T. Ardañaz, Pedro Jares, África García‐Orad, Miguel Ángel Pujana, Emili Montserrat, Sílvia de Sanjosé, Elı́as Campo	60
19	The purine nucleoside phosphorylase inhibitor forodesine induces p53-independent apoptosis in chronic lymphocytic leukemia through caspase-8 activation, Mcl-1 downregulation, conformational changes of Bax and Bak and ROS generation. 2007 ·Molecular Cancer Therapeutics ·Roberto Alonso, Neus Villamor, Ramanda Upshaw, Shanta Bantia, Thomas Mehrling, Elı́as Campo, Emili Montserrat, Dolors Colomer	2
20	Gene Expression Profiling of Acute Myeloid Leukemia with Translocation t(8;16)(p11;p13) and MYST3-CREBBP Rearrangement Reveals a Distinctive Signature with a Specific Pattern of HOX Gene Expression 2006 ·Cancer Research ·Mireia Camós, Jordi Esteve, Pedro Jares, Dolors Colomer, Marı́a Rozman, Neus Villamor, Dolors Costa, Ana Carrió, Josep Nomdedéu, Emili Montserrat, Elı́as Campo	91

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact